Administration of Molnupiravir for COVID-19

PATIENT POPULATIONS

It is important to carefully evaluate and counsel patients prior to administering molnupiravir due to the potential adverse effects related to this medicine.

Women and persons who can get pregnant

- If clinically indicated, evaluate patient for pregnancy prior to starting molnupiravir for non-severe COVID-19.
- If administered, advise to use effective, consistent and reliable contraception while taking molnupiravir and for 4 days after completing the last dose.
- When sexually active with a man or person who can impregnate who has taken molnupiravir, advise to use an effective, consistent and reliable method of contraception for 3 months after completion of the treatment course.

Men of reproductive age and persons who can impregnate

- If sexually active with a woman or person who can get pregnant, advise use of an effective, consistent and reliable method of contraception for at least 3 months after completion of the treatment course.
- Non-clinical studies to fully assess the potential for molnupiravir to affect the offspring of treated fathers/parents have not been completed.

PREPARATION AND ADMINISTRATION

Molnupiravir is a capsule administered orally (by mouth). Instruct patients to take the following measures when taking this medicine at home:

1. Wash hands.
2. Obtain correct dose, 800 mg of molnupiravir (4 x 200 mg capsules) of molnupiravir.
3. Swallow capsules whole with plenty of fluid. The medication can be taken with or without food.
4. Advise patients not to stop treatment course early, even if they feel better, as completion of treatment is important to reduce the risk of antiviral resistance, which can lead to reduced efficacy of drug.
5. Advise patients that if they do not tolerate this medicine, to immediately discuss with their health care provider early stopping of treatment.

Missed or forgotten doses

- If a patient forgets to take a dose of molnupiravir within 10 hours of the time it is usually taken, they should take it as soon as possible and take the next dose at the usual time.
- If a patient forgets to take a dose of molnupiravir by more than 10 hours, they should NOT take the missed dose and take the next one at the usual time.
- Double doses should NOT be taken to make up for missed doses.

Overdosage

- In the event of treatment overdose with Molnupiravir, general supportive measures should be adopted including monitoring of vital signs and observation of the clinical status of the patient.
- There is no specific antidote for overdose with Molnupiravir.